Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses the outcome of the Myeloma X and XI trials. Dr Ramasamy firstly discusses the Phase III Myeloma X trial (NCT00747877), which showed clear improvement in time to progression and improved overall survival (OS) for patients having a second transplant. Dr Ramasamy then discusses the Phase III Myeloma XI trial (NCT01554852) involving a combination of carfilzomib, cyclophosphamide, revlimid and dexamethasone, which was presented with updated data by Dr Charlotte Pawlyn of the Institute of Cancer Research, London; this four drug combination upfront in transplant eligible patients showed very impressive response rates. Dr Ramasamy then discusses the next big trial, Myeloma XV, which is currently being planned. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.